Literature DB >> 1686210

ICI D7114 a novel selective beta-adrenoceptor agonist selectively stimulates brown fat and increases whole-body oxygen consumption.

B R Holloway1, R Howe, B S Rao, D Stribling, R M Mayers, M G Briscoe, J M Jackson.   

Abstract

1. ICI D7114 is a novel, beta-adrenoceptor agonist which stimulates whole body oxygen consumption in conscious rats, cats and dogs and brown adipose tissue (BAT) activity in conscious rats. Treatment of rats with ICI D7114 stimulated oxygen consumption (ED50, 0.04 mg kg-1, p.o.) and BAT mitochondrial guanosine diphosphate (GDP)-binding (ED50, 0.15 mg kg-1, p.o.) with no chronotropic effects on the heart at these doses. 2. Reference beta-adrenoceptor agonists, isoprenaline and clenbuterol, also stimulated oxygen consumption and BAT activity but were less selective because they also produced effects on heart rate at these doses. 3. Treatment of conscious rats with ICI D7114 did not attenuate the chronotropic effects on the heart of a subsequent isoprenaline challenge. 4. Administration of ICI D7114 or of its acid metabolite had no effect in a cat soleus muscle model of tremor or on blood potassium levels in the conscious dog, indicating lack of effects at beta 2-adrenoceptors. 5. The results indicate that ICI D7114 may have activity at atypical beta-adrenoceptors in brown adipose tissue leading to increased whole body oxygen consumption.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1686210      PMCID: PMC1908265          DOI: 10.1111/j.1476-5381.1991.tb12391.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  THERMOGENESIS OF BROWN ADIPOSE TISSUE IN COLD-ACCLIMATED RATS.

Authors:  R E SMITH; J C ROBERTS
Journal:  Am J Physiol       Date:  1964-01

2.  The effects of adrenaline, noradrenaline and isoprenaline on skeletal muscle contractions in the cat.

Authors:  W C BOWMAN; E ZAIMIS
Journal:  J Physiol       Date:  1958-11-10       Impact factor: 5.182

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Molecular characterization of the human beta 3-adrenergic receptor.

Authors:  L J Emorine; S Marullo; M M Briend-Sutren; G Patey; K Tate; C Delavier-Klutchko; A D Strosberg
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

5.  Kalemotropic effect of epinephrine: analysis with adrenergic agonists and antagonists.

Authors:  E P Todd; R L Vick
Journal:  Am J Physiol       Date:  1971-06

6.  Effect of caloric restriction on energy expenditure in obese patients.

Authors:  G A Bray
Journal:  Lancet       Date:  1969-08-23       Impact factor: 79.321

7.  Hamster brown-adipose-tissue mitochondria. Purine nucleotide control of the ion conductance of the inner membrane, the nature of the nucleotide binding site.

Authors:  D G Nicholls
Journal:  Eur J Biochem       Date:  1976-02-16

8.  The thermogenic role of adipose tissue in the dog.

Authors:  B R Holloway; D Stribling; S Freeman; L Jamieson
Journal:  Int J Obes       Date:  1985

9.  Immunological, histological and biochemical assessment of brown adipose tissue activity in neonatal, control and beta-stimulant-treated adult dogs.

Authors:  M Ashwell; D Stirling; S Freeman; B R Holloway
Journal:  Int J Obes       Date:  1987

10.  Weight loss in obese subjects on a restricted diet given BRL 26830A, a new atypical beta adrenoceptor agonist.

Authors:  A A Connacher; R T Jung; P E Mitchell
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-30
View more
  16 in total

Review 1.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Beta 3-adrenergic receptor stimulation restores message and expression of brown-fat mitochondrial uncoupling protein in adult dogs.

Authors:  O Champigny; D Ricquier; O Blondel; R M Mayers; M G Briscoe; B R Holloway
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

3.  Challenges in β(3)-Adrenoceptor Agonist Drug Development.

Authors:  Jonathan R S Arch
Journal:  Ther Adv Endocrinol Metab       Date:  2011-04       Impact factor: 3.565

4.  Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects.

Authors:  J A Bennett; A E Tattersfield
Journal:  Thorax       Date:  1997-05       Impact factor: 9.139

5.  Beta 1- and beta 2-adrenoceptor antagonist activities of ICI-215001, a putative beta 3-adrenoceptor agonist.

Authors:  B Tesfamariam; G T Allen
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

6.  Receptor for catecholamines responding to catechol which potentiates voltage-dependent calcium current in single cells from guinea-pig taenia caeci.

Authors:  K Muraki; T B Bolton; Y Imaizumi; M Watanabe
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

7.  Characterization of propranolol-resistant (-)-[125I]-cyanopindolol binding sites in rat soleus muscle.

Authors:  S J Roberts; P Molenaar; R J Summers
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

8.  Evaluation of ICI D7114, a putative stimulant of brown adipocytes, on histamine-contracted guinea-pig ileum.

Authors:  J W Growcott; C Wilson; B Holloway; S Mainwaring
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

9.  Effects of selective antagonism of beta-adrenoceptor sub-types on responses to isoprenaline in rat distal colon in vitro.

Authors:  A MacDonald; M Lamont
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

10.  Effects on energy utilization of a beta3-adrenergic agonist in rats fed on a cafeteria diet.

Authors:  B Berraondo; A Bonafonte; M P Fernandez-Otero; J A Martinez
Journal:  Eat Weight Disord       Date:  1997-09       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.